Keywords Topics Show all (7) (-) Antiretroviral Therapy (ART) (5) ART-Drug Interactions & Side Effects (2) Rapid Start of ART (1) HIV Primary Care (1) HIV Prevention (1) Type ShareSpot Post (5) Publication Date Show all (5) (-) 2016 (5) Displaying 1 - 5 of 5 Tissue Levels of TAF: Too Low for PrEP? Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 03/17/2016 Switching from TDF/FTC to TAF/FTC Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 03/18/2016 Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy Jennifer Cocohoba UCSF Center for HIV Information, National AETC Support Center ShareSpot Post, published 04/12/2016 HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 09/27/2016 HIV Meds Update - RAPID: Immediate ART Initiation Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 09/27/2016
Tissue Levels of TAF: Too Low for PrEP? Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 03/17/2016
Switching from TDF/FTC to TAF/FTC Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 03/18/2016
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy Jennifer Cocohoba UCSF Center for HIV Information, National AETC Support Center ShareSpot Post, published 04/12/2016
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 09/27/2016
HIV Meds Update - RAPID: Immediate ART Initiation Susa Coffey National AETC Support Center, UCSF Center for HIV Information ShareSpot Post, published 09/27/2016
